State-based Reform
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
Affordable Care Act, Caught my eye, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 1/30/26
Read more: AMP is WAC — 1/30/26This week I had to remind myself that we live in the AND. Things can be truly awful around us, but there are still moments of happiness and hope. There are some periods in life where it is harder to find the AND, but it is there. At least that is what I have to…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Healthcare Costs, ICER, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 12/19/25
Read more: AMP is WAC — 12/19/25Today we’re expecting to hear more about manufacturer Most Favored Nation (MFN) agreements and (if you trust the rumors) maybe more about the MFN demos – the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model. I wasn’t planning on publishing the next two weeks,…
-
340B, Affordable Care Act, CMMI, FDA, Inflation Reduction Act, Medicaid, Medicare Part D, State-based ReformAMP is WAC — 11/21/25
Read more: AMP is WAC — 11/21/25This week felt weirdly calm – I am sure I just jinxed it. No AMP is WAC next week. If something interesting happens, I’m sure I won’t be able to help myself and will post on LinkedIn. Have a great Thanksgiving and I hope you remember that nothing will change that person at the table,…
-
Biosimilars, Caught my eye, Generics, Health Equity, ICER, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit Managers, State-based Reform, Utilization Management, ValueAMP is WAC — 10/31/25
Read more: AMP is WAC — 10/31/25You won’t be surprised when I tell you that my favorite Halloween costume was when I wore a pair of scrubs with vinyl records attached (Spin Doctor). Yep. Right up there with Freudian slips. This year I will stick to my usual costume: the nice lady who hands out full-size bars to 200+ neighborhood kids.…
-
CMMI, Drug Prices, Drug shortages, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Supply ChainAMP is WAC — 10/17/25
Read more: AMP is WAC — 10/17/25Caught my Eye Cool Idea, But. The Food and Drug Administration (FDA) puts announced a new pilot prioritization program for the review of Abbreviated New Drug Applications (ANDAs) to support generic manufacturing in the U.S. I mean it sounds good, except… there are three criteria for applicants: Only 9% of API manufacturers are in the…
-
340B, Caught my eye, DTC, Medicaid, Medicare Negotiation, Medicare Part D, Reference Pricing, State-based ReformAMP is WAC — 10/10/25
Read more: AMP is WAC — 10/10/25Going crazy? Or is it just a party of one? This past month as been brutal. My house has been a parade of plumbers and HVAC and electricians. Plus, visits to orthopedists and veterinarians and car mechanics. If the universe is trying to say something, all I’m hearing is that I’m scoring a ton of…
-
Affordable Care Act, Caught my eye, Employers, Healthcare Costs, Medicaid, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 9/19/25
Read more: AMP is WAC — 9/19/25Work travel is usually a nice change of pace. And then I found myself on a Wednesday afternoon on the NJ Turnpike in torrential rain with other cars facing the wrong direction. Super fun! Two good things – 1) the pharma team I gave the talk to was awesome and 2) made it home safe…
-
Inflation Reduction Act, Medicare Advantage, Medicare Part D, Reference Pricing, State-based Reform, Supply Chain, VaccinesAMP is WAC — 8/15/25
Read more: AMP is WAC — 8/15/25Caught my Eye Surely a Coincidence. President Trump called for direct to consumer purchasing at Most Favored Nation Pricing and BlinkRx said that they could offer this service. Donald Trump Jr. is on their board. Lobby Me This. Stat News had an article about a new coalition, IRA Watch, that is formed to discuss…
Latest news
- AMP is WAC — 03/13/26
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
Categories
- 340B (63)
- Affordable Care Act (22)
- Alzheimer's (11)
- Biosimilars (32)
- Caught my eye (101)
- Cell and Gene (6)
- Chevron Deference (2)
- CMMI (27)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (7)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (68)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (77)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (27)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)